Immunocore FY2027 EPS Forecast Increased by HC Wainwright

Key Points

• HC Wainwright has raised its FY2027 EPS forecast for Immunocore from $1.10 to $1.12 and maintains a "Buy" rating with a target price of $100.00.
• Immunocore recently reported a quarterly earnings performance of -$0.20 EPS, surpassing analyst expectations, with a revenue of $130.65 million, reflecting a 30% year-over-year increase.
• Institutional investors control 84.50% of Immunocore, with significant recent activity from various hedge funds increasing their stakes in the company.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Equities research analysts at HC Wainwright upped their FY2027 earnings estimates for shares of Immunocore in a research report issued to clients and investors on Tuesday, August 12th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $1.12 per share for the year, up from their prior forecast of $1.10. HC Wainwright has a "Buy" rating and a $100.00 price target on the stock. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore's FY2029 earnings at $7.88 EPS.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The company had revenue of $130.65 million during the quarter, compared to analyst estimates of $122.96 million. During the same period in the previous year, the business earned ($0.23) EPS. The firm's revenue for the quarter was up 30.0% on a year-over-year basis.

IMCR has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunocore in a research report on Tuesday, May 27th. They set a "buy" rating and a $65.00 price objective for the company. Finally, Oppenheimer boosted their price objective on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Immunocore presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $32.48 on Wednesday. The company has a quick ratio of 5.86, a current ratio of 5.89 and a debt-to-equity ratio of 1.01. Immunocore has a twelve month low of $23.15 and a twelve month high of $39.33. The firm has a market cap of $1.63 billion, a P/E ratio of -81.36 and a beta of 0.77. The company has a 50 day moving average of $33.88 and a 200 day moving average of $31.23.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in Immunocore in the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Immunocore by 4,696.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company's stock valued at $41,000 after purchasing an additional 1,268 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of Immunocore during the second quarter valued at approximately $42,000. Oppenheimer Asset Management Inc. bought a new position in shares of Immunocore during the first quarter valued at approximately $225,000. Finally, Checkpoint Capital L.P. bought a new position in shares of Immunocore during the first quarter valued at approximately $267,000. Institutional investors own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.